End-stage hemolytic rate of leukocyte-reduced RBCs in additive solution: a 5-year retrospective study
10.13303/j.cjbt.issn.1004-549x.2022.11.016
- VernacularTitle:去白细胞悬浮红细胞保存期末溶血率的5年回顾性研究
- Author:
Yanhong WAN
1
;
Yanyu LI
1
;
Wen LIU
1
;
Shijing PEI
2
Author Information
1. Taiyuan Blood Centre, Taiyuan 030024, China
2. Shanxi Center of Clinical Laboratories
- Publication Type:Journal Article
- Keywords:
end-stage hemolytic rate;
quality standard
- From:
Chinese Journal of Blood Transfusion
2022;35(11):1157-1159
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the suitability of current quality standard for end-stage hemolytic rate required by Quality Requirements for Whole Blood and Blood Components in Taiyuan through a 5- year retrospective analysis of leukocyte-reduced RBCs in additive solution in Taiyuan Blood Center. 【Methods】 A total of 240 packs of leukocyte-reduced RBCs in additive solution were collected from January 2007 to December 2021. Hb concentration, hematocrit(Hct) and free Hb in supernatant at end-stage were detected to measure the hemolytic rate. And the hemolytic rate was then compared with the current standard(0.8%) to analyze whether statistical differences existed. 【Results】 The hemolytic rate of leukocyte-reduced RBCs in additive solution were 0.109±0.123 in 2017, 0.113±0.085 in 2018, 0.121±0.076 in 2019, 0.101±0.057 in 2020, and 0.128±0.089 in 2021, with no significant difference among each other (P>0.05). And 97.5% of the products showed an end-stage hemolytic rate below 0.4%, 0.83% among 0.6%~0.7%, and none over the standard of 0.8%. 【Conclusion】 The current national standard for end-stage hemolytic rate of leukocyte-reduced RBCs in additive solution might not be suitable for blood quality control in Taiyuan, and a much stricter criteria should be considered.
